Saturday, November 14, 2026

Goldman Sachs and Citigroup shed $15B+ in traditional banking assets while building private credit partnerships

Goldman Sachs and Citigroup divested non-core banking units worth over $15 billion while forming $105 billion in private credit and wealth management partnerships between 2024-2026. Goldman's stock rose 20.5% in six months following acquisitions of Industry Ventures and Innovator Capital Management. Citigroup partnered with Apollo, BlackRock, and Carlyle on alternative investment platforms after cutting 20,000 jobs.

From our archive, published before source-traceability. How we work

Goldman Sachs and Citigroup shed $15B+ in traditional banking assets while building private credit partnerships
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Goldman Sachs sold its Polish TFI unit to ING in November 2025 while acquiring Industry Ventures in January 2026 and Innovator Capital Management in December 2025. The stock climbed 20.5% over six months, and the firm raised its dividend 12.5% in January 2026 and 33.3% in July 2025.

Citigroup sold Russian subsidiary AO Citibank in February 2026 and equity stakes in Grupo Financiero Banamex the same month. The bank announced 20,000 job cuts in January 2024 as part of its restructuring plan.

These divestitures funded partnerships in higher-margin segments. Citigroup formed a $25 billion private credit platform with Apollo in September 2024, an $80 billion customized portfolio offering with BlackRock in September 2025, and an asset-based private credit partnership with Carlyle in June 2025. Combined, these alternative investment platforms total $105 billion.

JPMorgan acquired Apple's credit card program in January 2026 and completed the General Motors credit card program transition in September 2025. The moves signal major banks redirecting capital from international retail operations toward technology-enabled consumer finance and institutional alternative investments.

Goldman's acquisition of Industry Ventures and Innovator Capital Management expands its private market and ETF capabilities. The firm's dividend increases followed these strategic acquisitions, suggesting investor confidence in the wealth management pivot.

Citigroup's exit from Russia and Mexico retail banking eliminates regulatory complexity and capital requirements in emerging markets. The $105 billion in alternative investment partnerships with Apollo, BlackRock, and Carlyle shifts the bank toward fee-based revenue with lower capital intensity than traditional lending.

The pattern shows banks trading balance sheet-heavy operations for asset-light wealth management and private credit. Goldman's 20.5% stock gain and dual dividend raises demonstrate market approval of this strategy. Citigroup's simultaneous workforce reduction and partnership expansion indicates a fundamental business model shift.

Traditional banking revenue faces compression from low interest margins and regulatory capital requirements. Private credit and wealth management generate fees without equivalent balance sheet risk. The $105 billion in Citigroup partnerships and Goldman's acquisition spree represent a sector-wide reallocation toward these higher-margin segments.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com